Clinical trials
Cardiotoxicity clinical trials
Below are recruiting cardiotoxicity clinical trials, each written for real people, not researchers. We’re tracking 53 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07426913Recruiting
Virtual reality heart health for breast cancer survivors
This trial tests if a virtual reality program can help breast cancer survivors taking certain chemotherapies improve their heart health. It's for people currently receiving trastuzumab or anthracycline-based treatment, along with immunotherapy, for their first breast cancer diagnosis.
Richmond, VirginiaAges 18 years+ - NCT03934905RecruitingPhase 1/Phase 2
Sulforaphane supplement to protect the heart during doxorubicin
This trial tests whether a nutritional supplement called sulforaphane (SFN) can help protect heart function in people with breast cancer who are receiving doxorubicin (a chemotherapy that can affect the heart). Participants take caplets and have heart and safety monitoring to see if the supplement reduces heart-related side effects.
Lubbock, TexasAges 18–89 - NCT07158450Enrolling by invitation
Heart health check for cancer patients
This trial tests a new device that monitors heart health during cancer treatment. It uses a simple on-body sensor alongside your regular echocardiogram to see if it can detect heart changes early.
Golden, ColoradoAges 18 years+ - NCT06332131Enrolling by invitation
Heart blood vessel effects of immunotherapy in breast and lung cancer
This trial studies whether immunotherapy drugs (called immune checkpoint inhibitors) affect the small blood vessels of the heart. If you have breast cancer or lung cancer and are starting a specific treatment plan, you may be asked to have a special heart scan before and during therapy.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06211413Enrolling by invitation
Tracking heart issues in CLL patients on BTK inhibitors
This study watches for high blood pressure and irregular heartbeats in people with CLL who are starting a type of targeted therapy called a BTK inhibitor (acalabrutinib or zanubrutinib). Researchers will use a smartwatch and blood pressure cuff to monitor your heart health at home.
Philadelphia, PennsylvaniaAges 22 years+
Hear when a new Cardiotoxicity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for cardiotoxicity?
- Yes. Clin2 currently lists 53 recruiting cardiotoxicity studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a cardiotoxicity trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a cardiotoxicity trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.